Immunotherapy has changed the way physicians treat cancer patients. This approach to therapy targets the immune system to redirect cells toward the tumor. | Immunology ...

JSKN003 is an anti-HER2 biparatopic ADC, which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new UVA Cancer Center research ...

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early ...

Ovarian tumors, often detected incidentally, pose a diagnostic challenge that requires careful management. Decisions depend on assessing the malignancy risk and addressing patient symptoms. For benign ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a ...

Tumor immune evasion mechanisms could be reversed by activating intracellular antiviral immune responses. It has been reported that the use of DNA methyltransferase (DNMT) inhibitors combined with ...